Alzamend Neuro IncAlzamend Neuro Inc
Alzamend Neuro Inc

Alzamend Neuro Inc

ALZN
Health Care·Biotechnology

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Florida; U.S.A
Market cap
No dataNo data
Revenue
No dataNo data
Net income
$-8.8M−94.3% YoY
Free cash flow
$-8.1M−17.5% YoY

Market

Listed stock
ALZNPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
No dataNo data
Operating income
$-8.8M−95.0% YoY
Net income
$-8.8M−94.3% YoY
Free cash flow
$-8.1M−17.5% YoY

Revenue, profit & cash trend

Revenue
Reference
Revenue: 2022 $0, 2023 $0, 2024 $0. Reference line: Reference at $0.

Growth & profitability

Revenue growth
No dataNo data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2022-04-30 $-12.3M, 2023-04-30 $-14.9M, 2024-04-30 $-9.9M, 2025-04-30 $-4.5M, 2026-04-30 $-8.8M. Net income: 2022-04-30 $-12.4M, 2023-04-30 $-14.9M, 2024-04-30 $-9.9M, 2025-04-30 $-4.5M, 2026-04-30 $-8.8M. Free cash flow: 2022-04-30 $-6.6M, 2023-04-30 $-8.9M, 2024-04-30 $-8.4M, 2025-04-30 $-6.9M, 2026-04-30 $-8.1M

Growth heatmap

20232024CAGR
Revenue
No data
No data
No data
Gross profit
No data
No data
No data
Operating income
-20.7%
+33.2%
+54.7%
-95.0%
No data
Free cash flow
-34.9%
+5.7%
+18.4%
-17.5%
No data

Earnings quality

Operating cash flow
$-8.1M−22.8% YoY
Net income
$-8.8M−94.3% YoY
Free cash flow
$-8.1M−17.5% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2026-04-30 92%, 2025-04-30 145%, 2024-04-30 83%, 2023-04-30 60%, 2022-04-30 54%. Free cash flow: 2026-04-30 92%, 2025-04-30 152%, 2024-04-30 85%, 2023-04-30 60%, 2022-04-30 54%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data